Bristol Myers cell therapy succeeds in trial
Bristol Myers Squibb announced its experimental cell therapy achieved significant response rates in advanced multiple myeloma patients. The mid-stage trial met its main goal by showing meaningful improvement for patients who exhausted standard options.
Xurve View
Insights:
Xurve View
BRISTOL-MYERS SQUIBB CO reported on Tuesday afternoon that its experimental cell therapy met its main goal in a mid-stage trial for advanced blood cancer. The study evaluated arlocabtagene autoleucel in patients with multiple myeloma who had exhausted standard treatments. The trial showed a statistically significant improvement in overall response rates.
